Wengel Kathryn E
SEC CIK 1745955 · EDGAR
BoughtSold
Most active insiders at JNJ, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Duato Joaquin | CEO, COB, Dir | — | $66.84M |
| 2 | Wolk Joseph J | EVP, CFO | — | $21.77M |
| 3 | REED JOHN C | EVP, Innovative Medicine, R, D | — | $17.29M |
| 4 | Swanson James D. | EVP, CIO | — | $15.11M |
| 5 | Schmid Timothy | EVP, WW COB, MedTech | — | $15.08M |
| 6 | Broadhurst Vanessa | EVP, Gbl Corp Affairs | — | $7.30M |
| 7 | Forminard Elizabeth | EVP, CLO | — | $4.09M |
| 8 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | — | $3.95M |
| 9 | Wengel Kathryn E | EVP, Chief TO, Risk Off | — | $2.41M |
| 10 | Decker Robert J | VP Corp. Ctrl | — | $1.01M |
Transactions 36
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-12 17:23 | 2026-06-11 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $115.67 | +10.0K | 124.3K | +9% | +$1.16M |
| D | 2026-06-12 17:23 | 2026-06-11 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | S - Sale+OE | $241.15 | -10.0K | 114.3K | -8% | -$2.41M |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $0.00 | +15.6K | 114.6K | +16% | $0 |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $244.45 | -7,266 | 114.3K | -6% | -$1.78M |
| D | 2026-02-13 | 2026-02-11 | LH | Labcorp | Wengel Kathryn E | Dir | M - OptEx | — | +897 | 4,133 | +28% | — |
| D | 2026-02-09 19:40 | 2026-02-06 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $101.87 | +38.9K | 133.2K | +41% | +$3.97M |
| D | 2026-02-09 19:40 | 2026-02-06 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $239.99 | -27.3K | 106.0K | -20% | -$6.54M |
| DM | 2025-02-18 21:16 | 2025-02-13+ | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $0.00 | +8,625 | 96.7K | +10% | $0 |
| DM | 2025-02-18 21:16 | 2025-02-14+ | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $156.58 | -3,296 | 94.3K | -3% | -$516.1K |
| D | 2025-02-11 19:42 | 2025-02-07 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $100.06 | +32.8K | 115.0K | +40% | +$3.28M |
| D | 2025-02-11 19:42 | 2025-02-07 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $153.12 | -26.1K | 89.0K | -23% | -$3.99M |
| D | 2025-02-10 | 2025-02-06 | LH | Labcorp | Wengel Kathryn E | Dir | M - OptEx | — | +944 | 3,236 | +41% | — |
| D | 2024-02-15 16:53 | 2024-02-13 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $0.00 | +651 | 82.6K | +0.8% | $0 |
| D | 2024-02-15 16:53 | 2024-02-13 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $157.85 | -333 | 82.3K | -0.4% | -$52.6K |
| DM | 2024-02-14 18:36 | 2024-02-12 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $0.00 | +13.8K | 89.0K | +18% | $0 |
| D | 2024-02-14 18:36 | 2024-02-12 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $157.40 | -7,066 | 81.9K | -8% | -$1.11M |
| D | 2024-02-13 17:18 | 2024-02-09 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $90.44 | +35.6K | 102.5K | +53% | +$3.22M |
| D | 2024-02-13 17:18 | 2024-02-09 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $156.76 | -27.3K | 75.2K | -27% | -$4.28M |
| D | 2024-02-12 19:25 | 2024-02-08 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $0.00 | +1,971 | 67.9K | +3% | $0 |
| D | 2024-02-12 19:25 | 2024-02-08 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $156.33 | -1,009 | 66.9K | -1% | -$157.7K |
| D | 2024-02-08 | 2024-02-07 | LH | Labcorp | Wengel Kathryn E | Dir | M - OptEx | — | +947 | 2,292 | +70% | — |
| 2023-06-14 16:19 | 2023-06-12 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | S - Sale | $160.00 | -12.5K | 65.9K | -16% | -$1.99M | |
| D | 2023-02-15 19:25 | 2023-02-13 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | A - Grant | $0.00 | +10.8K | 83.3K | +15% | $0 |
| D | 2023-02-15 19:25 | 2023-02-13 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $162.01 | -4,891 | 78.4K | -6% | -$792.4K |
| D | 2023-02-14 16:37 | 2023-02-10 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $0.00 | +1,807 | 73.1K | +3% | $0 |
| D | 2023-02-14 16:37 | 2023-02-10 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $162.08 | -667 | 72.5K | -0.9% | -$108.1K |
| D | 2023-02-14 | 2023-02-11 | LH | Labcorp | Wengel Kathryn E | Dir | M - OptEx | — | +742 | 1,345 | +123% | — |
| D | 2022-11-10 16:47 | 2022-11-09 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief GSC Off | M - OptEx | $72.54 | +16.4K | 87.7K | +23% | +$1.19M |
| D | 2022-11-10 16:47 | 2022-11-09 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief GSC Off | S - Sale+OE | $173.42 | -16.4K | 71.3K | -19% | -$2.85M |
| D | 2022-06-14 18:28 | 2022-06-10 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief GSC Off | M - OptEx | $72.54 | +40.0K | 111.3K | +56% | +$2.90M |
| DM | 2022-06-14 18:28 | 2022-06-10 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief GSC Off | S - Sale+OE | $173.00 | -40.0K | 71.3K | -36% | -$6.92M |
| D | 2022-03-29 | 2022-03-25 | LH | Labcorp | Wengel Kathryn E | Dir | M - OptEx | — | +603 | 603 | New | — |
| D | 2022-02-17 06:01 | 2022-02-15 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief GSC Off | M - OptEx | $0.00 | +10.4K | 76.0K | +16% | $0 |
| D | 2022-02-17 06:01 | 2022-02-15 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief GSC Off | F - Tax | $165.89 | -4,699 | 71.3K | -6% | -$779.5K |
| D | 2022-02-15 20:03 | 2022-02-14 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief GSC Off | M - OptEx | $0.00 | +1,896 | 66.3K | +3% | $0 |
| D | 2022-02-15 20:03 | 2022-02-14 | JNJ | Johnson & Johnson | Wengel Kathryn E | EVP, Chief GSC Off | F - Tax | $168.85 | -695 | 65.6K | -1% | -$117.4K |
Purchase Sale Sale after option exercise All abbreviations